Literature DB >> 30632529

Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease.

Eunju Jung1, Chang-Hee Suh1, Hyoun-Ah Kim1, Ju-Yang Jung1.   

Abstract

OBJECTIVES: This study aims to compare the clinical characteristics of systemic sclerosis (SSc) patients with or without interstitial lung disease (ILD), and figure out whether the differences can be useful to suspect ILD in SSc. PATIENTS AND METHODS: We retrospectively collected the clinical data of 108 patients with SSc (13 males, 95 females; mean age 50.1±13.5 years; range 14 to 78 years) and compared them according to the presence of ILD. ILD was confirmed by chest computed tomography, and pulmonary arterial hypertension was suspected when right ventricular systolic pressure was ≥40 mmHg based on echocardiography.
RESULTS: Of the 108 patients, 49 (45.4) had diffuse type and 59 (54.6) had limited type SSc. Disease duration, percentages of positive anti-scleroderma 70 (anti-Scl70) antibody and anti-centromere antibody, white blood cell, platelet, erythrocyte sedimentation rate (ESR), and presence of pulmonary hypertension differed significantly. On multivariate logistic analysis, positive titer of anti-Scl70 antibody (odds ratio [OR]=15.65, p<0.001), platelet (OR=1.01, p=0.026), ESR (OR=1.02, p=0.037) and pulmonary hypertension (OR=21.97, p=0.003) were associated with ILD in patients with SSc.
CONCLUSION: In SSc patients with ILD, disease duration was longer and positive titer of anti-Scl70 antibody was more frequent, positive titer of anti- centromere antibody was less frequent, and white blood cell and platelet counts, ESR levels, and incidence of possible pulmonary hypertension were significantly higher than in those without ILD. Positive titer of anti-Scl70 antibody, platelet, ESR, and combination of pulmonary hypertension were independently associated with the presence of ILD in SSc patients.

Entities:  

Keywords:  Interstitial lung diseases; pulmonary hypertension; systemic sclerosis

Year:  2018        PMID: 30632529      PMCID: PMC6328216          DOI: 10.5606/ArchRheumatol.2018.6630

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  29 in total

1.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 2.  Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.

Authors:  S M Proudman; W M Stevens; J Sahhar; D Celermajer
Journal:  Intern Med J       Date:  2007-07       Impact factor: 2.048

Review 3.  Scleroderma.

Authors:  Armando Gabrielli; Enrico V Avvedimento; Thomas Krieg
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

Review 4.  Geoepidemiology of systemic sclerosis.

Authors:  Brigitte Ranque; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2009-11-10       Impact factor: 9.754

5.  Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.

Authors:  Marc Humbert; Azzedine Yaici; Pascal de Groote; David Montani; Olivier Sitbon; David Launay; Virginie Gressin; Loïc Guillevin; Pierre Clerson; Gérald Simonneau; Eric Hachulla
Journal:  Arthritis Rheum       Date:  2011-11

6.  Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey.

Authors:  Ferit Zuhur; Sayid Shafi Zuhur; Cigdem Zuhur; Benan Musellim; Gul Ongen
Journal:  Rheumatol Int       Date:  2011-03-05       Impact factor: 2.631

7.  Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.

Authors:  Terry A McNearney; John D Reveille; Michael Fischbach; Alan W Friedman; Jeffrey R Lisse; Niti Goel; Filemon K Tan; Xiaodong Zhou; Chul Ahn; Carol A Feghali-Bostwick; Marvin Fritzler; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2007-03-15

8.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.

Authors:  U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

9.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

10.  Interstitial lung disease in systemic sclerosis: a simple staging system.

Authors:  Nicole S L Goh; Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Susan J Copley; Toby M Maher; Tamera J Corte; Clare R Sander; Jonathan Ratoff; Anand Devaraj; Gracijela Bozovic; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

View more
  5 in total

1.  Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients.

Authors:  Lichong Shen; Qingran Yan; Xiaoxiang Chen
Journal:  Arch Rheumatol       Date:  2019-08-26       Impact factor: 1.472

2.  Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.

Authors:  Meihua Qiu; Xueyuan Nian; Lingling Pang; Pengfei Yu; Shenchun Zou
Journal:  Int J Rheum Dis       Date:  2021-08-21       Impact factor: 2.558

3.  CXCR2 May Serve as a Useful Index of Disease Activity in Interstitial Lung Disease Associated With Primary Sjögren's Syndrome.

Authors:  Xiaofang Zhu; Saisai Lu; Lixia Zhu; Mengjiao Yu; Tingting Wei; Xiaochun Zhu; Dan Chen; Chengshui Chen
Journal:  Front Mol Biosci       Date:  2021-05-13

4.  Association of quantitative computed tomography ındices with lung function and extent of pulmonary fibrosis in patients with systemic sclerosis.

Authors:  Duygu Temiz Karadag; Ozgur Cakir; Senar San; Ayten Yazici; Ercument Ciftci; Ayse Cefle
Journal:  Clin Rheumatol       Date:  2021-09-16       Impact factor: 2.980

Review 5.  Clinical Overview of Progressive Fibrotic Interstitial Lung Disease.

Authors:  Amy Hajari Case
Journal:  Front Med (Lausanne)       Date:  2022-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.